Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Rheumatology

What Is the Life Expectancy for Someone With Lupus?

At a Glance

Thanks to modern treatments, the vast majority of people with systemic lupus erythematosus (SLE) can expect to live a normal or near-normal lifespan. While lupus requires careful management, 10-year survival rates now exceed 95 percent in developed nations.

It is completely normal to worry about your lifespan when you are first diagnosed with systemic lupus erythematosus (SLE). The most important thing to know is this: thanks to modern medical advancements, the vast majority of people with lupus can expect to live a normal or near-normal lifespan [1]. While lupus is a serious chronic illness, it is no longer the life-limiting diagnosis it was decades ago.

Modern Survival Rates

Over the last several decades, survival rates for people with lupus have dramatically improved [1]. Today, studies show that 10-year survival rates exceed 95% in developed nations [2][3]. Furthermore, 15- to 20-year survival rates generally range from 85% to 90%, and doctors emphasize that these long-term statistics reflect older eras of medicine [4]. Because medical research moves quickly, today’s newly diagnosed patients are expected to do even better.

This incredible progress is largely due to early diagnosis and better medications. The drug hydroxychloroquine has become a cornerstone of lupus treatment, helping to prevent flares and protect internal organs [5]. Additionally, newer biologic medications, such as belimumab and anifrolumab, have been introduced to specifically target the immune system, improving safety and effectiveness for those with moderate-to-severe disease [6][7].

However, it is important to acknowledge that lupus still carries an elevated mortality risk compared to the general population [8]. On average, the mortality risk is roughly 2.6 times higher than that of someone without the disease [9]. How the disease impacts your specific life expectancy depends heavily on your age, sex, and ethnic background. For example, lupus tends to be more severe—and carries a higher mortality risk—for women of African American, Hispanic, and Indigenous descent, highlighting the need for aggressive, early treatment in these groups [10][11].

The “Two-Peak” Pattern of Risk

When doctors look at health risks in lupus, they often refer to a “bimodal” or two-peak pattern. This simply means that the risks to your health tend to fall into two distinct timeframes: early in your diagnosis, and many years later.

1. Early Risks (First few years after diagnosis)

In the first few years after a lupus diagnosis, the most significant threats to life are severe disease flares and infections [2][3].

  • Infections: Because lupus involves an overactive immune system, and many treatments (like corticosteroids and immunosuppressants) intentionally suppress it, patients have a high risk of severe infections. Infections are consistently ranked as a leading cause of early mortality [2][12].
  • Active Disease and Organ Damage: Severe inflammation early on can cause rapid damage. Lupus nephritis (kidney involvement) is a severe complication that significantly increases early health risks [13][14]. Crucially, early kidney involvement is often “silent” or symptom-free, which is why your doctor will constantly ask for routine urine and blood tests.

2. Late Risks (10+ years after diagnosis)

If you have had lupus for a decade or more, the nature of the risk shifts. Late-stage mortality is most commonly linked to cardiovascular disease (heart and blood vessel issues) [12].

  • Heart Disease: The chronic inflammation caused by lupus accelerates the development of atherosclerosis (plaque buildup in the arteries) [15][16]. Even with modern treatments, the risk of cardiovascular death for someone with lupus is nearly double that of the general population [12].
  • Medication Side Effects: Long-term use of certain medications, particularly glucocorticoids (steroids), is also associated with a higher risk of heart disease and stroke [17].
  • Cancer: People with lupus face a slightly higher risk of certain cancers, such as lymphoma or cervical cancer, which can become a factor later in life [18].

Taking Control of Your Future

Understanding these risks isn’t meant to scare you; it is meant to empower you. Knowing what the risks are means you can actively work to prevent them.

You can protect your long-term health by:

  • Taking your medications consistently: Adhering to baseline therapies like hydroxychloroquine protects your organs over the long term.
  • Preventing infections: Stay up to date on vaccines and communicate with your doctor quickly if you develop a fever.
  • Managing heart health: Ask your doctor for regular cardiovascular screenings (like annual cholesterol panels), eat a heart-healthy diet, control your blood pressure, and do not smoke.
  • Minimizing steroids: Work with your rheumatologist to find a long-term treatment plan that reduces your reliance on steroids.
  • Practicing sun protection: UV exposure can trigger systemic disease flares that lead to internal organ damage, so wearing sunscreen and avoiding intense midday sun is a critical, controllable risk factor.

Common questions in this guide

Can I live a normal lifespan with systemic lupus erythematosus?
Yes. Thanks to modern medical advancements and earlier diagnoses, the vast majority of people with lupus can expect to live a normal or near-normal lifespan. Ten-year survival rates now exceed 95 percent in developed nations.
What are the most common health risks immediately after a lupus diagnosis?
In the first few years after diagnosis, the primary health risks are severe disease flares, infections, and active organ damage. Early kidney involvement, known as lupus nephritis, is a severe complication that requires close monitoring through regular urine and blood tests.
How does lupus affect my long-term heart health?
After having lupus for a decade or more, cardiovascular disease becomes the leading health risk. The chronic inflammation associated with lupus accelerates plaque buildup in the arteries, making heart-healthy lifestyle choices and regular cholesterol screenings essential.
Why do people with lupus have a higher risk of infections?
Lupus causes an overactive immune system, and the medications used to treat it intentionally suppress your immune response to prevent organ damage. This combination makes it harder for your body to fight off germs, putting you at a much higher risk for developing severe infections.
What can I do to improve my long-term prognosis with lupus?
You can protect your long-term health by consistently taking your baseline medications like hydroxychloroquine, staying up to date on vaccines, managing your heart health, working with your doctor to minimize steroid use, and practicing strict sun protection.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific blood and urine tests will we run regularly to catch 'silent' complications like lupus nephritis early?
  2. 2.Based on my age, ethnicity, and current symptoms, do I have any elevated risk factors we should be watching more closely?
  3. 3.What is our long-term plan to minimize my use of steroids like prednisone?
  4. 4.When should I start seeing a cardiologist, or how frequently will we screen my cholesterol and blood pressure?
  5. 5.Which vaccinations do you recommend I receive or update to help protect me against serious infections?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Risk factors for mortality in systemic lupus erythematosus patients: Analysis of adult and pediatric cohorts in Taiwan.

    Lai CC, Sun YS, Chen WS, et al.

    Journal of the Chinese Medical Association : JCMA 2022; (85(11)):1044-1050 doi:10.1097/JCMA.0000000000000783.

    PMID: 36343272
  2. 2

    Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus.

    Mu L, Hao Y, Fan Y, et al.

    Lupus 2018; (27(10)):1742-1752 doi:10.1177/0961203318789788.

    PMID: 30060721
  3. 3

    Long-term Outcomes of Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study from CSTAR Registry.

    Wang Z, Li M, Ye Z, et al.

    Rheumatology and immunology research 2021; (2(3)):195-202 doi:10.2478/rir-2021-0025.

    PMID: 36465068
  4. 4

    Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort.

    A Mohammed RH, Lotfy Fayed H, Ibrahim Emara N

    Lupus 2022; (31(5)):628-636 doi:10.1177/09612033221081691.

    PMID: 35306918
  5. 5

    GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model.

    Toumi E, Bestion E, Militello M, et al.

    British journal of pharmacology 2025; (182(16)):3786-3799 doi:10.1111/bph.70058.

    PMID: 40258389
  6. 6

    Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.

    Chatham WW, Furie R, Saxena A, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(5)):816-825 doi:10.1002/art.41598.

    PMID: 33225631
  7. 7

    Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

    Wallace DJ, Ginzler EM, Merrill JT, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(7)):1125-1134 doi:10.1002/art.40861.

    PMID: 30771238
  8. 8

    Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis.

    Lee YH, Choi SJ, Ji JD, Song GG

    Lupus 2016; (25(7)):727-34 doi:10.1177/0961203315627202.

    PMID: 26811368
  9. 9

    Epidemiology of systemic lupus erythematosus.

    Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS

    Expert review of clinical immunology 2017; (13(8)):799-814 doi:10.1080/1744666X.2017.1327352.

    PMID: 28471259
  10. 10

    Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015.

    Yen EY, Singh RR

    Arthritis & rheumatology (Hoboken, N.J.) 2018; (70(8)):1251-1255 doi:10.1002/art.40512.

    PMID: 29671279
  11. 11

    Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort.

    Cann MP, Sage AM, McKinnon E, et al.

    Lupus 2022; (31(2)):246-255 doi:10.1177/09612033211069765.

    PMID: 35037500
  12. 12

    Mortality in systemic lupus erythematosus: causes, predictors and interventions.

    Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ

    Expert review of clinical immunology 2018; (14(12)):1043-1053 doi:10.1080/1744666X.2018.1538789.

    PMID: 30338717
  13. 13

    [Lupus nephritis].

    Schreiber J, Eisenberger U, de Groot K

    Der Internist 2019; (60(5)):468-477 doi:10.1007/s00108-019-0574-y.

    PMID: 30840107
  14. 14

    Lupus nephritis.

    Anders HJ, Saxena R, Zhao MH, et al.

    Nature reviews. Disease primers 2020; (6(1)):7 doi:10.1038/s41572-019-0141-9.

    PMID: 31974366
  15. 15

    Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism.

    Pan Q, Huang X, Liu C, et al.

    Frontiers in immunology 2025; (16()):1492726 doi:10.3389/fimmu.2025.1492726.

    PMID: 40356907
  16. 16

    Systemic lupus erythematosus is a risk factor for cardiovascular disease: a nationwide, population-based study in Korea.

    Lim SY, Bae EH, Han KD, et al.

    Lupus 2018; (27(13)):2050-2056 doi:10.1177/0961203318804883.

    PMID: 30282562
  17. 17

    Cardiovascular disease risk in Korean patients with systemic lupus erythematosus compared to diabetes mellitus and the general population.

    Han JY, Cho SK, Jeon Y, et al.

    Scientific reports 2025; (15(1)):3208 doi:10.1038/s41598-025-87740-y.

    PMID: 39863730
  18. 18

    Six Autoimmune Disorders Are Associated With Increased Incidence of Gastric Cancer: A Systematic Review and Meta-Analysis of Half a Million Patients.

    Zádori N, Szakó L, Váncsa S, et al.

    Frontiers in immunology 2021; (12()):750533 doi:10.3389/fimmu.2021.750533.

    PMID: 34887857

This page provides general information about life expectancy and survival rates for systemic lupus erythematosus. It does not replace professional medical advice. Always consult your rheumatologist to understand how your specific health profile impacts your prognosis.

Get notified when new evidence is published on Systemic lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.